Summary
77 / 100 · Bulios Score
What speaks for it
- Out of every 100 INR of revenue, 33 INR is left as net profit.
- The share price is below the Bulios Fair Price.
- Revenue grew by 15% a year over the last 3 years.
What to watch
- Analysts expect revenue to fall by 21% this fiscal year.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapPrice against the Bulios Fair Price
P/E against the industry (Drug Manufacturers - Specialty & Generic)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 12.4 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to fall by 21%.
Growth in detailDoes it make money?
Very wellWhere 100 INR of revenue goes
- Cost of sales 24 INR
- Sales and administration 52 INR
- Taxes and other -8.3 INR
- Net profit 33 INR
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 19 INR
Out of every 100 INR of revenue, 33 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.19%
- Paid out of profit
- 2.3%
You receive ₹1.50 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail